Reem Ghalib

13.0k total citations · 3 hit papers
47 papers, 3.1k citations indexed

About

Reem Ghalib is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Reem Ghalib has authored 47 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hepatology, 26 papers in Epidemiology and 9 papers in Infectious Diseases. Recurrent topics in Reem Ghalib's work include Hepatitis C virus research (31 papers), Liver Disease Diagnosis and Treatment (22 papers) and Hepatitis B Virus Studies (13 papers). Reem Ghalib is often cited by papers focused on Hepatitis C virus research (31 papers), Liver Disease Diagnosis and Treatment (22 papers) and Hepatitis B Virus Studies (13 papers). Reem Ghalib collaborates with scholars based in United States, Belgium and Canada. Reem Ghalib's co-authors include Eric Lawitz, Mitchell L. Shiffman, Bruce R. Bacon, Lisa M. Nyberg, Mark Sulkowski, K. Rajender Reddy, John G. McHutchison, Clifford A. Brass, Stephanie Noviello and Janice K. Albrecht and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Reem Ghalib

47 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

2009 889 citations John G. McHutchison, Eric Lawitz et al. New England Journal of Medicine profile →
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

2012 454 citations Anna S. Lok, David Gardiner et al. New England Journal of Medicine profile →
Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

2015 386 citations Stefan Zeuzem, Reem Ghalib et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Reem Ghalib United States	18	2.7k	2.3k	547	259	251	47	3.1k
María‐Carlota Londoño Spain	28	2.2k 0.8×	1.7k 0.7×	270 0.5×	720 2.8×	159 0.6×	125	2.9k
Mauricio Lisker‐Melman United States	23	2.3k 0.8×	2.0k 0.9×	248 0.5×	278 1.1×	378 1.5×	79	2.8k
Hélène Fontaine France	23	3.0k 1.1×	3.2k 1.4×	339 0.6×	255 1.0×	159 0.6×	58	3.9k
Sabela Lens Spain	26	2.4k 0.9×	2.1k 0.9×	237 0.4×	205 0.8×	155 0.6×	119	2.7k
Mauro Viganò Italy	27	2.2k 0.8×	2.4k 1.0×	285 0.5×	160 0.6×	88 0.4×	131	2.9k
Luz Martı́n-Carbonero Spain	39	2.4k 0.9×	2.3k 1.0×	2.1k 3.9×	111 0.4×	99 0.4×	159	4.2k
Miriam Levy Australia	24	1.5k 0.5×	1.5k 0.7×	262 0.5×	274 1.1×	122 0.5×	64	2.5k
Jing‐Houng Wang Taiwan	38	4.0k 1.5×	3.7k 1.6×	212 0.4×	591 2.3×	108 0.4×	215	4.9k
Greg Galler United States	9	1.2k 0.4×	1.7k 0.8×	210 0.4×	381 1.5×	193 0.8×	13	2.4k
Eugenia Vispo Spain	31	1.9k 0.7×	1.8k 0.8×	1.1k 2.1×	64 0.2×	167 0.7×	104	2.9k

Countries citing papers authored by Reem Ghalib

Since Specialization

Citations

This map shows the geographic impact of Reem Ghalib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reem Ghalib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reem Ghalib more than expected).

Fields of papers citing papers by Reem Ghalib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reem Ghalib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reem Ghalib. The network helps show where Reem Ghalib may publish in the future.

Co-authorship network of co-authors of Reem Ghalib

This figure shows the co-authorship network connecting the top 25 collaborators of Reem Ghalib. A scholar is included among the top collaborators of Reem Ghalib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reem Ghalib. Reem Ghalib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shillcutt, Sasha K., et al.. (2019). Survey of Women Physicians' Experience with Elected Leadership Positions. Health Equity. 3(1). 162–168. 11 indexed citations

Zamor, Philippe J., John Dillon, Douglas E. Dylla, et al.. (2019). OUTCOMES OF PATIENTS INTERRUPTING GLECAPREVIR/PIBRENTASVIR TREATMENT: A CASE SERIES FROM CLINICAL TRIALS. Hepatology. 70. 2 indexed citations

Zamor, Philippe J., John M. Vierling, Reem Ghalib, et al.. (2018). Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 clinical Trials. The American Journal of Gastroenterology. 113(6). 863–871. 2 indexed citations

Forns, Xavier, Samuel S. Lee, Joaquin Valdes, et al.. (2017). Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. The Lancet Infectious Diseases. 17(10). 1062–1068. 234 indexed citations

Forns, Xavier, Sam Lee, Joaquin Valdes, et al.. (2017). EXPEDITION-I: Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis. Gastroenterology. 152(5). S1061–S1061. 2 indexed citations

Harrison, S., Vlad Ratziu, Mitchell L. Shiffman, et al.. (2017). Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis. Journal of Hepatology. 66(1). S159–S160. 1 indexed citations

Loomba, Rohit, Eric Lawitz, Reem Ghalib, et al.. (2017). Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in nonalcoholic steatohepatitis (NASH). Journal of Hepatology. 66(1). S671–S671. 5 indexed citations

Nelson, David R., Daniel Bernstein, B. Freilich, et al.. (2015). P0782 : All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-experienced patients infected with HCV genotype (GT) 3: A subanalysis of the ALLY-3 phase 3 study. Journal of Hepatology. 62. S624–S624. 9 indexed citations

Nelson, David R., David Bernstein, Bradley Freilich, et al.. (2015). 1016 All-Oral 12-Week Combination Treatment With Daclatasvir (DCV) and Sofosbuvir (SOF) in Treatment-Experienced Patients Infected With HCV Genotype (GT) 3: A Subanalysis of the Ally-3 Phase 3 Study. Gastroenterology. 148(4). S–1003. 3 indexed citations

10.

Lawitz, Eric, Edwin DeJesus, Eric M. Yoshida, et al.. (2015). Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2). Hepatology. 64(2). 360–369. 142 indexed citations

11.

Lok, Anna S., David Gardiner, Eric Lawitz, et al.. (2012). Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. New England Journal of Medicine. 366(3). 216–224. 454 indexed citations breakdown →

12.

Melia, Michael T., Andrew J. Muir, Jonathan McCone, et al.. (2011). Racial differences in hepatitis C treatment eligibility. Hepatology. 54(1). 70–78. 36 indexed citations

13.

Bacon, Bruce R., Mitchell L. Shiffman, Flavia Mendes, et al.. (2009). Retreating chronic hepatitis C with daily interferon alfacon‐1/ribavirin after nonresponse to pegylated interferon/ribavirin. Hepatology. 49(6). 1838–1846. 60 indexed citations

14.

Pockros, Paul J., David R. Nelson, Eliot Godofsky, et al.. (2008). R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin†. Hepatology. 48(2). 385–397. 74 indexed citations

15.

Bisceglie, Adrian M. Di, Reem Ghalib, Fayez M. Hamzeh, & Vinod K. Rustgi. (2007). Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C*. Journal of Viral Hepatitis. 14(10). 721–729. 66 indexed citations

16.

Balan, Vijayan, David H. Schwartz, George Y. Wu, et al.. (2005). Erythropoietic Response to Anemia in Chronic Hepatitis C Patients Receiving Combination Pegylated Interferon/Ribavirin. The American Journal of Gastroenterology. 100(2). 299–307. 49 indexed citations

17.

Russo, Mark W., et al.. (2005). Randomized trial of pegylated interferon α-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation. 21(2). 437–443. 71 indexed citations

18.

Ghalib, Reem, Manal M. Hassan, John A. Goss, et al.. (2003). Recombinant Human Interleukin–11 Improves Thrombocytopenia in Patients With Cirrhosis. Hepatology. 37(5). 1165–1171. 22 indexed citations

19.

Ghalib, Reem, Risë Stribling, Terry Box, et al.. (2003). Treatment of recurrent hepatitis C after liver transplantation with pegylated interferon alfa-2b plus ribavirin. Preliminary analysis. Gastroenterology. 124(4). A694–A694. 4 indexed citations

20.

Chalasani, Naga, Arthur R. Baluyut, Gagan Sood, et al.. (2000). Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology. 31(1). 7–11. 226 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact